CVE:QPT

Quest PharmaTech Competitors

C$0.10
-0.01 (-9.52 %)
(As of 04/14/2021 03:55 PM ET)
Add
Compare
Today's Range
C$0.10
Now: C$0.10
C$0.11
50-Day Range
C$0.11
MA: C$0.17
C$0.20
52-Week Range
C$0.10
Now: C$0.10
C$0.32
Volume122,300 shs
Average Volume48,919 shs
Market CapitalizationC$15.94 million
P/E Ratio0.15
Dividend YieldN/A
BetaN/A

Competitors

Quest PharmaTech (CVE:QPT) Vs. NVH, PDP, MBX, SBM, PMN, and COV

Should you be buying QPT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Quest PharmaTech, including Novoheart (NVH), Pediapharm (PDP), Microbix Biosystems (MBX), Sirona Biochem (SBM), ProMIS Neurosciences (PMN), and Covalon Technologies (COV).

Novoheart (CVE:NVH) and Quest PharmaTech (CVE:QPT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings for Novoheart and Quest PharmaTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novoheart0000N/A
Quest PharmaTech0000N/A

Earnings & Valuation

This table compares Novoheart and Quest PharmaTech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95
Quest PharmaTechC$38,871.00409.98C$109.88 millionC$0.660.15

Quest PharmaTech has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novoheart and Quest PharmaTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoheartN/AN/AN/A
Quest PharmaTechN/AN/AN/A

Summary

Quest PharmaTech beats Novoheart on 4 of the 5 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares Quest PharmaTech and Pediapharm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
PediapharmN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Quest PharmaTech and Pediapharm, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
Pediapharm0000N/A

Earnings & Valuation

This table compares Quest PharmaTech and Pediapharm's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00409.98C$109.88 millionC$0.660.15
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11

Quest PharmaTech has higher earnings, but lower revenue than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Summary

Quest PharmaTech beats Pediapharm on 4 of the 5 factors compared between the two stocks.

Microbix Biosystems (TSE:MBX) and Quest PharmaTech (CVE:QPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Microbix Biosystems and Quest PharmaTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Microbix Biosystems0000N/A
Quest PharmaTech0000N/A

Profitability

This table compares Microbix Biosystems and Quest PharmaTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Microbix BiosystemsN/AN/AN/A
Quest PharmaTechN/AN/AN/A

Earnings and Valuation

This table compares Microbix Biosystems and Quest PharmaTech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$11.64 million5.64C$-5,581,797.00C($0.05)-11.76
Quest PharmaTechC$38,871.00409.98C$109.88 millionC$0.660.15

Quest PharmaTech has lower revenue, but higher earnings than Microbix Biosystems. Microbix Biosystems is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Summary

Quest PharmaTech beats Microbix Biosystems on 4 of the 5 factors compared between the two stocks.

Sirona Biochem (CVE:SBM) and Quest PharmaTech (CVE:QPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Profitability

This table compares Sirona Biochem and Quest PharmaTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sirona BiochemN/AN/AN/A
Quest PharmaTechN/AN/AN/A

Earnings and Valuation

This table compares Sirona Biochem and Quest PharmaTech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sirona BiochemC$123,870.00643.26C$-2,959,580.00C($0.01)-26.92
Quest PharmaTechC$38,871.00409.98C$109.88 millionC$0.660.15

Quest PharmaTech has lower revenue, but higher earnings than Sirona Biochem. Sirona Biochem is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sirona Biochem and Quest PharmaTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sirona Biochem0000N/A
Quest PharmaTech0000N/A

Summary

Quest PharmaTech beats Sirona Biochem on 3 of the 5 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Quest PharmaTech and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00409.98C$109.88 millionC$0.660.15
ProMIS NeurosciencesC$1,787.0029,105.48C$-6,119,000.00C($0.02)-8.50

Quest PharmaTech has higher revenue and earnings than ProMIS Neurosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Quest PharmaTech and ProMIS Neurosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
ProMIS Neurosciences0000N/A

Profitability

This table compares Quest PharmaTech and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Summary

Quest PharmaTech beats ProMIS Neurosciences on 4 of the 5 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and Covalon Technologies (CVE:COV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Quest PharmaTech and Covalon Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
Covalon Technologies0000N/A

Valuation & Earnings

This table compares Quest PharmaTech and Covalon Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00409.98C$109.88 millionC$0.660.15
Covalon TechnologiesC$23.84 million1.55C$-6,144,922.00C($0.24)-6.01

Quest PharmaTech has higher earnings, but lower revenue than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest PharmaTech and Covalon Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
Covalon TechnologiesN/AN/AN/A

Summary

Quest PharmaTech beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.


Quest PharmaTech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.60-1.7%C$65.67 millionC$11.64 million-11.76News Coverage
Gap Down
SBM
Sirona Biochem
0.5$0.35-5.7%C$58.80 millionC$123,870.00-26.92
PMN
ProMIS Neurosciences
0.5$0.17-8.8%C$56.60 millionC$1,787.00-8.50Gap Up
COV
Covalon Technologies
0.6$1.43-0.0%C$37.44 millionC$23.84 million-6.01Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27-3.7%C$34.02 millionC$13.02 million-0.39
IGX
IntelGenx Technologies
0.9$0.60-10.0%C$30.87 millionC$1.54 million-9.23High Trading Volume
News Coverage
CZO
Ceapro
0.6$0.78-0.0%C$21.65 millionC$16.14 million23.64Gap Up
CTX
Crescita Therapeutics
0.6$0.84-1.2%C$17.34 millionC$15.64 million420.00News Coverage
KNE
Kane Biotech
0.4$0.16-0.0%C$14.12 millionC$1.34 million-4.57Gap Down
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.10-5.3%C$12.70 millionN/A-4.32Gap Down
NSP
Naturally Splendid Enterprises
0.6$0.06-8.3%C$11.06 millionC$2.03 million-1.40Gap Up
MPH
Medicure
0.7$1.58-1.3%C$10.80 millionC$12.71 million-1.02
BTI
Bioasis Technologies
0.7$0.39-1.3%C$10.16 millionC$4.12 million35.00
HEM
Hemostemix
0.6$0.45-2.2%C$9.07 millionN/A-2.68Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.37-1.4%C$6.94 millionC$5.60 million6.76News Coverage
Gap Down
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$4.00-12.5%C$4.48 millionN/A-1.29High Trading Volume
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$45.95-3.2%C$0.00C$267.59 million50.49News Coverage
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66News Coverage
Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.